进口与国产紫杉醇治疗卵巢恶性肿瘤的疗效和药物经济学评价

Effective and pharmacoeconomic evaluation on different paclitaxel in treatment of ovarian carcinoma

目的比较进口与国产紫杉醇治疗卵巢恶性上皮性肿瘤(EOC)的疗效和经济学效果。方法 72例EOC患者按手术残余灶大小及使用进口紫杉醇和国产紫杉醇分为TS组(进口紫杉醇且术后残余病灶直径≤1 cm)和PS组(国产紫杉醇且术后残余病灶直径≤1 em)、TU组(进口紫杉醇且术后残余病灶直径>1cm)和PU组(国产紫杉醇且术后残余病灶直径>1 cm)。4个化疗周期结束后评价疗效和不良反应,并用最小成本分析法进行药物经济学研究。结果 TS组vs PS组和TU组vs PU组第1～4疗程治疗效果与不良反应差异均无统计学意义(P>0.05),进口紫杉醇-卡铂与国产紫杉醇-卡铂两种治疗方案成本分别为44073.89元和12 689.89元。结论进口与国产紫杉醇对EOC患者的近期疗效相似,国产紫杉醇-卡铂治疗EOC患者在药物经济学上优于进口紫杉醇-卡铂方案。

AIM To evaluate effectiveness and pharrnacoeconomics on different paclitaxel in the treatment of epithelial ovarian carcinoma（EOC）. METHODS Seventy-two patients with EOC were assigned to TS group（imported paclitaxel and residual tumor≤ 1 cm after surgery）, PS group（ local paclitaxel and residual tumor≤ 1 cm after surgery）, TU group（imported paclitaxel and residual tumor 〉 1 cm after surgery）and PU group（local paclitaxel and residual tumor〉 1 cm after surgery）. After treatment for 4 regimen, costminimization analysis were conducted. RESULTS There were no statistical significances on effectiveness and adverse drug reactions between various groups（ P 〉 0.05）. The cost of imported paclitaxel-carboplatin group and local paclitaxel-earboplatin group were 44 073.89 yuan and 12 689.89 yuan,respectively（ P 〈 0.05）. CONCLUSION Considering pharmacoeconomics, local paelitaxel-carboplatin program is superior to imported paclitaxel-carboplatin program for EOC.